BSX — Boston Scientific Cashflow Statement
0.000.00%
Last trade - 00:00- $102.80bn
- $112.51bn
- $20.07bn
Annual cashflow statement for Boston Scientific, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 1,041 | 698 | 1,592 | 1,846 | 2,892 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 212 | 761 | 487 | 851 | 522 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -351 | -1,006 | -771 | -462 | -246 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 1,871 | 1,526 | 2,503 | 3,434 | 4,534 |
| Capital Expenditures | -554 | -588 | -711 | -790 | -876 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -1,043 | -1,423 | -1,863 | -4,897 | -1,764 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Change in Net Investments | |||||
| Change in Net Intangibles | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -1,597 | -2,011 | -2,574 | -5,687 | -2,640 |
| Financing Cash Flow Items | -150 | -464 | -145 | -243 | -186 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -95 | -548 | 5 | 1,814 | -395 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 173 | -1,042 | -70 | -450 | 1,541 |